AbstractObjective To examine the protein expression of the nucleotide excision repair gene (ERCC-1) in patients with locally advanced cervical cancer and its relationship with the efficacy of radiotherapy and chemotherapy. Methods The expression of ERCC-1 protein in 88 patients with locally advanced cervical cancer treated in our hospital between 2007-2011 was measured using immunohistochemistry (IHC). The patients were divided into high-expression group (n=48) and low-expression group (n=40) based on the fluorescence intensity on the IHC staining. All patients received cisplatin (40 mg/m2 per week) during radiotherapy. The relationship between ERCC-1 protein expression and the clinicopathological factors of cervical cancer was analyzed using the chi-square test. Survival was calculated using the Kaplan-Meier method and compared by the log-rank test. Multivariate prognostic analysis was performed using the Cox model. Results The overall response rate (CR+PR) was 81%(39/48) in the high-ERCC-1 expression group and 85%(34/40) in the low-ERCC-1 expression group (P=0.641). ERCC-1 protein expression was associated with recurrence and metastasis (P=0.043,0.043). The 5-year survival rate was significantly higher in the low-ERCC-1 expression group than in the high-ERCC-1 expression group (65% vs. 42%, P=0.029). Conclusions Patients with high ERCC-1 protein expression are more likely to have local recurrence and distant metastasis than those with low ERCC-1 protein expression. ERCC-1 protein expression may be a clinically significant biomarker for predicting the prognosis of cervical cancer patients.
Corresponding Authors:
Sun Hong,Email:qdsunhong@126.com
Cite this article:
Zhang Zhongxin,Li Wei,Sun Hong. Expression of ERCC-1 protein and its clinical implication in locally advanced cervical cancer[J]. Chinese Journal of Radiation Oncology, 2017, 26(9): 1033-1037.
Zhang Zhongxin,Li Wei,Sun Hong. Expression of ERCC-1 protein and its clinical implication in locally advanced cervical cancer[J]. Chinese Journal of Radiation Oncology, 2017, 26(9): 1033-1037.
[1] Jemal A,Bray F,Center MM,et al. Global cancer statistics[J].CA Cancer J Clin,2011,61:69-90. [2] Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.DOI:10.3322/caac.21332. [3] 杨雪,附舰,康艳霞,等.调强适形放射治疗联合每周紫杉醇+卡铂方案在宫颈癌术前同步放化疗的临床观察[J].中国肿瘤临床与康复,2013,20(9):1027-1028.DOI:10.13455/j.cnki.cjcor.2013.09.018. Yang X,Fu J,Kang YX,et al. Clinical observation of intensity-modulated radiotherapy combined with weekly paclitaxel plus carboplatin chemotherapy in cervical carcinoma[J].Chin Clin Oncol Rehab,2013,20(9):1027-1028.DOI:10.13455/j.cnki.cjcor.2013.09.018. [4] Gaffney DK,Erickson-Wittmann BA,Jhingran A,et al. ACR appropriateness criteriaon advanced cervical cancer expert panel on radiation oncology-gynecology[J].Int J Radiat Oncol Biol Phys 2011,81(3):609-614.DOI:10.1016/j.ijrobp.2010.11.005. [5] Jadon R,Pembroke CA,Hanna CL,et al. A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer[J].Clin Oncol,2014,26(4):185-196.DOI:10.1016/j.clon.2013.11.031. [6] Eminowicz G,Hall-Craggs M,Diez P,et al. Improving target volume delineation in intact cervical carcinoma:literature review and step-by-step pictorial atlas to aid contouring[J].Pract Radiat Oncol,2016,6(5):e203-e213.DOI:10.1016/j.prro.2016.01.006. [7] Klopp AH,Yeung AR,Deshmukh S,et al. A phase Ⅲ randomized trial comparing patient-reported toxicity and quality of life (QOL) during pelvic intensity modulated radiation therapy as compared to conventional radiation therapy[J].Int J Radiat Oncol Biol Phys,2016,96(S2):S3.DOI:10.1016/j.ijrobp.2016.06.024. [8] 中华医学会妇产科学会,《中华妇产科杂志》编辑委员会.妇科常见恶性肿瘤诊断与治疗规范(草案)[J].中华妇产科杂志,1998,33(11):694-704. Institute of Obstetrics and Gynecology of Chinese Medical Association,editorial board of Chinese Journal of Obstetrics and Gynecology. The common gynecological malignant tumor diagnosis and treatment standard (Draft)[J].Chin J Obst Gynecol,1998,33(11):694-704. [9] Donnelly ED,Rfaat T,Gentile M,et al. Evaluation of outcomes in patients with carcinoma of the cervix treated with concurrent radiation and cisplatin versus cisplatin/5-FU compared with radiation alone[J].Am J Clin Oncol,2015,38(5):437-441.DOI:10.1097/COC.0b013e3182a1b448. [10] 范立,郭汝元,高伟,等.3DCRT治疗早期宫颈癌的临床观察[J].中国药物与临床杂志,2012,5(6):418-420. Fan L,Guo RY,Gao W,et al. Three-dimensional conformal radiotherapy for early cervical cancer[J].Chin Remed Clin,2012,5(6):418-420. [11] Keys HM,Bundy BN,Stehman FB,et al. Cisplatin,radiation,and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage ⅠB cervical carcinoma[J].N Engl J Med,1999,340(15):1154-1161.DOI:10.1056/NEJM199904153401503. [12] Peters Ⅲ WA,Liu PY,Barrett Ⅱ RJ,et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix[J].J Clin Oncol,2000,18(8):1606-1613.DOI:10.1128/IAI.01257-08. [13] Dunkern TR,Kaina B.Cell proliferation and DNA breaks are involved in ultraviolet light-induced apoptosis in nucleotide excision repair-deficient Chinese hamster cells[J].Mol Biol Cell,2002,13(1):348-361.DOI:10.1091/mbc.01-05-0225. [14] Reed E.Platinum-DNA adduct,nucleotide excision repair and platinum based anti-cancer chemotherapy[J].Cancer Treat Rev,1998,24(5):331-344.DOI:10.1016/S0305-7372(98)90056-1.[15] Bourguignon MH,Gisone PA,Perez MR,et al. Genetic and epigenetic features in radiation sensitⅣity Part I:cell signalling in radiation response[J].Eur J Nucl Med Mol Imaging,2005,32(2):229-246.DOI:10.1007/s00259-004-1730-7. [16] Xu QY,Gao Y,Liu Y,et al. Identification of differential gene expression profiles of radioresistant lung cancer cell line established by fractionated ionizing radiation in vitro[J].Chin Med J,2008,121(18):1830-1837. [17] Olaussen KA,Mountzios G,Soria JC.ERCC-1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer[J].Curr Opin Pulm Med,2007,13(4):284-289.DOI:10.1097/MCP.0b013e32816b5c63. [18] Kirschner K,Melton DW.Multiple roles of the ERCC-1-XPF endonuclease in DNA repair and resistance to anticancer drugs[J].Anticancer Res,2010,30(9):3223-3232. [19] McNeil EM,Melton DW.DNA repair endonuclease ERCC-1-XPF as a novel Therapeutic target to overcome chemoresistance in cancer therapy[J].Nucl Acids Res,2012,40(20):9990-10004.DOI:10.1093/nar/gks818. [20] Manandhar M,Boulware KS,Wood RD.The ERCC-1 and ERCC4(XPF) genes and gene products[J].Gene,2015,569(2):153-161.DOI:10.1016/j.gene.2015.06.026. [21] Guo WF,Lin RX,Huang J,et al. Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis[J].Radiat Res,2005,164(1):27-35.DOI:10.1667/RR3401. [22] Jeong J,Hong SJ,Ju YJ,et al. Temporal cDNA microarray analysis of gene expression in human hepatocellular carcinoma upon radiation exposure[J].Oncol Rep,2006,15(1):33-48.DOI:10.3892/or.15.1.33. [23] Doll CM,Craighead P,Diaz R,et al. High ERCC-1 expression is associated with worse survival in patients with locally advanced cervical cancer treated with radiotherapy (RT):an evaluation of AQUAversus conventional IHC methods[J].Int J Radiat Oncol Biol Phys,2008,72(S1):S18-S19.DOI:10.1016/j.ijrobp.2008.06.807. [24] Kim MK,Cho KJ,Kwon GY,et al. ERCC-1 predicting chemoradiation resistance and poor outcome in oesophageal cancer[J].Eur J Cancer,2008,44(1):54-60.DOI:10.1016/j.ejca.2007.09.006. [25] Azuma K,Sasada T,Kawahara A,et al. Expression of ERCC-1 and class Ⅲβ-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation[J].Cancer Chemother Pharmacol,2009,64(3):565-573.DOI:10.1007/s00280-008-0907-3. [26] Sun JM,Ahn MJ,Park MJ,et al. Expression of excision repair cross-complementation group 1 as predictⅣ e marker for nasopharyngeal cancer Treated with concurrent chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2011,80(3):655-660.DOI:10.1016/j.ijrobp.2010.02.061.
2017, Vol. 26 
